• Paysign raised its full-year 2026 profitability outlook, projecting net income of $23 million-$24 million and adjusted EBITDA of $38.5 million-$40 million.
• Revenue guidance remained $114 million-$117 million, supported by patient affordability program launches.
• Third-quarter revenue rose 42.6% to $30.8 million; patient affordability revenue increased 109.8% to $16.6 million.
• A customer's transfer of 113 plasma centers to another provider is expected to reduce fourth-quarter revenue by $1.5 million.
• The November 9 earnings call included management participants Mark Newcomer, Jeff Baker, Matt Turner and Matt Lanford.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Paysign Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.